[144] Ionis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Ionis Pharmaceuticals Form 144 notice: A holder intends to sell 1,427 shares of Ionis common stock through Insight Securities on the NYSE. The shares were acquired as compensation from Ionis on 08/22/2025 and the planned sale date is listed as 08/22/2025. The filing reports no shares sold in the past three months by the seller. The filing states the seller represents they have no undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Small, routine insider sale notice for shares received as compensation; unlikely to be material to Ionis overall.

The Form 144 discloses a proposed sale of 1,427 common shares acquired as compensation on the same date as the planned sale, to be executed through Insight Securities on the NYSE. Against the issuer's outstanding share count shown in the filing (143,100,000), this represents an immaterial fraction of equity. The filing also notes no sales by the seller in the prior three months and includes the standard representation about lack of undisclosed material information. For investors, this document reads as a routine SEC notification required when insiders or related persons sell restricted or control securities, not a signal of material corporate change.

Compliance/Risk Analyst

TL;DR: Procedural compliance filing showing adherence to Rule 144 reporting for a small compensation-related sale.

The notice documents compliance with Rule 144 disclosure requirements: it identifies the broker, sale quantity, acquisition and planned sale dates, and the nature of acquisition as compensation. The explicit declaration that there were no sales in the prior three months helps establish the seller's recent trading history. From a regulatory and disclosure-risk perspective, the filing satisfies routine transparency obligations and does not indicate regulatory concern or irregular trading patterns based on the provided data.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON STOCK	INSIGHT SECURITIES, INC. 600 CENTRAL AVENUE STE 293 HIGHLAND PARK IL 60035	1427	60687.00	143100000	08/22/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON STOCK	08/22/2025	COMPENSATION	IONIS PHARMACEUTICALS, INC.			1427	08/22/2025	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ionis Pharmaceuticals' Form 144 (IONS) disclose?

The Form 144 discloses a proposed sale of 1,427 shares of Ionis common stock acquired as compensation, to be sold through Insight Securities on the NYSE.

When were the shares acquired and when is the planned sale date?

The shares were acquired on 08/22/2025 as compensation, and the approximate date of sale is also listed as 08/22/2025.

How large is the proposed sale relative to outstanding shares?

The filing lists 1,427 shares to be sold versus 143,100,000 shares outstanding as shown in the notice, indicating an immaterial proportion of total equity.

Did the filer report any securities sold in the past three months?

The filing states Nothing to Report for securities sold in the prior three months by the person for whose account the securities are to be sold.

Which broker is handling the proposed sale?

The broker named in the filing is Insight Securities, Inc. located at 600 Central Avenue, Highland Park, IL, and the sale is to occur on the NYSE.